Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares, rose in value on Friday, July 11, with the stock price down by -0.19% to the previous day’s close as strong demand from buyers drove the stock to $31.93.
Actively observing the price movement in the last trading, the stock closed the session at $31.99, falling within a range of $31.35 and $32.21. The value of beta (5-year monthly) was 0.28. Referring to stock’s 52-week performance, its high was $62.53, and the low was $24.10. On the whole, CRNX has fluctuated by -3.48% over the past month.
With the market capitalization of Crinetics Pharmaceuticals Inc currently standing at about $2.99 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRNX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CRNX currently trading nearly 4.87% and 2.45% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.06, while the 7-day volatility ratio is showing 4.49% which for the 30-day chart, stands at 3.82%. Furthermore, Crinetics Pharmaceuticals Inc (CRNX)’s beta value is 0.33.
A comparison of Crinetics Pharmaceuticals Inc (CRNX) with its peers suggests the former has fared considerably weaker in the market. CRNX showed an intraday change of -0.19% in last session, and over the past year, it shrunk by -37.55%%.
Data on historical trading for Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) indicates that the trading volumes over the past 10 days have averaged 0.93 and over the past 3 months, they’ve averaged 806.77K. According to company’s latest data on outstanding shares, there are 93.53 million shares outstanding.
Nearly 7.49% of Crinetics Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 104.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.32 million shares as on 2025-06-13, resulting in a short ratio of 13.49. According to the data, the short interest in Crinetics Pharmaceuticals Inc (CRNX) stood at 1254.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 10.16 million. The stock has fallen by -33.80% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRNX stock heading into the next quarter.
